Literature DB >> 8789858

Indocyanine green videoangiography of older patients with central serous chorioretinopathy.

R F Spaide1, L Hall, A Haas, L Campeas, L A Yannuzzi, Y L Fisher, D R Guyer, J S Slakter, J A Sorenson, D A Orlock.   

Abstract

PURPOSE: The authors studied the indocyanine green (ICG) videoangiography findings of central serous chorioretinopathy (CSC) in older adults.
BACKGROUND: Central serous chorioretinopathy in older adults may be confused with the exudative forms of age-related macular degeneration (AMD) because the two entities may have similar ophthalmoscopic and fluorescein angiographic findings. Because of its enhanced ability to image the choroidal circulation, ICG videoangiography has been used to describe certain choroidal vascular abnormalities in young adults with CSC, as well as older patients with choroidal neovascularization (CNV). The ICG videoangiography findings in CSC in older adults is largely unknown.
METHODS: The authors performed ICG videoangiography on 36 patients aged 50 years or older with CSC to characterize their findings.
RESULTS: The ICG videoangiography findings of the patients were consistent, revealing choroidal vascular hyperpermeability manifested by areas of hyperfluorescence that were first seen in the midphase of the angiogram. In the later phases of the angiogram, there were dispersion of the hyperfluorescence and a distinctive silhouetting of the larger choroidal vessels.
CONCLUSIONS: Older patients with CSC have a unique temporal and topographic pattern of hyperpermeability that can help establish the proper diagnosis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8789858     DOI: 10.1097/00006982-199616030-00004

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  90 in total

1.  [Central serous chorioretinopathy (CSC)].

Authors:  H Baraki; N Feltgen; J Roider; H Hoerauf; C Klatt
Journal:  Ophthalmologe       Date:  2010-05       Impact factor: 1.059

2.  [Experiences with chronic central serous chorioretinopathy treated with half-dose photodynamic therapy and verteporfin].

Authors:  M Töteberg-Harms; M Kurz-Levin; J Fleischhauer; R Windisch
Journal:  Ophthalmologe       Date:  2011-10       Impact factor: 1.059

3.  Morphological changes in the retinal pigment epithelium on spectral-domain OCT in the unaffected eyes with idiopathic central serous chorioretinopathy.

Authors:  Pawan Gupta; Vishali Gupta; M R Dogra; Ramandeep Singh; Amod Gupta
Journal:  Int Ophthalmol       Date:  2009-01-30       Impact factor: 2.031

4.  Transpupillary thermotherapy for chronic central serous chorioretinopathy.

Authors:  Nazimul Hussain; Rohit Khanna; Anjli Hussain; Taraprasad Das
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-01-13       Impact factor: 3.117

5.  Finasteride is effective for the treatment of central serous chorioretinopathy.

Authors:  E Moisseiev; A J Holmes; A Moshiri; L S Morse
Journal:  Eye (Lond)       Date:  2016-04-08       Impact factor: 3.775

6.  Acute central serous chorioretinopathy: a correlation study between fundus autofluorescence and spectral-domain OCT.

Authors:  Pierluigi Iacono; Parodi Maurizio Battaglia; Alexandros Papayannis; Carlo La Spina; Monica Varano; Francesco Bandello
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-01-08       Impact factor: 3.117

7.  One-year results of reduced fluence photodynamic therapy for central serous chorioretinopathy: the outer nuclear layer thickness is associated with visual prognosis.

Authors:  Yasuhiro Ohkuma; Takaaki Hayashi; Tsutomu Sakai; Akira Watanabe; Hiroshi Tsuneoka
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-03-02       Impact factor: 3.117

8.  Choroidal changes in eyes treated with high-dose systemic corticosteroids for optic neuritis.

Authors:  Jun Hyuk Lee; Ji Young Lee; Ho Ra; Nam Yeo Kang; Jiwon Baek
Journal:  Int J Ophthalmol       Date:  2020-09-18       Impact factor: 1.779

9.  Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level.

Authors:  W-M Chan; D S C Lam; T Y Y Lai; B S M Tam; D T L Liu; C K M Chan
Journal:  Br J Ophthalmol       Date:  2003-12       Impact factor: 4.638

10.  Efficacy of half-fluence photodynamic therapy depending on the degree of choroidal hyperpermeability in chronic central serous chorioretinopathy.

Authors:  S H Lim; W Chang; M Sagong
Journal:  Eye (Lond)       Date:  2013-03-01       Impact factor: 3.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.